Related references
Note: Only part of the references are listed.GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling
Chi-Chung Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
Christophe Depre et al.
HEADACHE (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
NEUROTHERAPEUTICS (2018)
Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential
Andrea Negro et al.
JOURNAL OF PAIN RESEARCH (2018)
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment
Stewart J. Tepper
HEADACHE (2018)
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
Stephen Landy et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
Stephen Landy et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine
Egilius L. H. Spierings et al.
CEPHALALGIA (2018)
Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis
Robin M. van Dongen et al.
CEPHALALGIA (2017)
Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan
Stephen Silberstein et al.
HEADACHE (2017)
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
Roger K. Cady et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Rapid systemic delivery of zolmitriptan using an adhesive dermally applied microarray
Donald J. Kellerman et al.
PAIN MANAGEMENT (2017)
A Critical Evaluation on MOH Current Treatments
Andrea Negro et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2017)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine
Tony W. Ho et al.
CEPHALALGIA (2016)
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss et al.
CEPHALALGIA (2016)
A Randomized Trial of Ketorolac vs Sumatripan vs Placebo Nasal Spray (KSPN) for Acute Migraine
Aruna S. Rao et al.
HEADACHE (2016)
Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ)
Paul Winner et al.
HEADACHE (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Metabotropic glutamate receptor 5: a target for migraine therapy
Maggie W. Waung et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
AVP-825 Breath-Powered Intranasal Delivery System Containing 22mg Sumatriptan Powder vs 100mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
Stewart J. Tepper et al.
HEADACHE (2015)
A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
Roger K. Cady et al.
HEADACHE (2015)
Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks
Baltazar Gomez-Mancilla et al.
CEPHALALGIA (2014)
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
Ronald Marcus et al.
CEPHALALGIA (2014)
Efficacy of BMS-927711 and other gepants vs triptans: There seem to be other players besides CGRP
Julio Pascual
CEPHALALGIA (2014)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Tony W. Ho et al.
NEUROLOGY (2014)
Therapeutic Prospects for Migraine: Can Paradise Be Regained?
Peter J. Goadsby
ANNALS OF NEUROLOGY (2013)
Sumatriptan: treatment across the full spectrum of migraine
Stephen D. Silberstein et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Clinical Implications for Breath-Powered Powder Sumatriptan Intranasal Treatment
Stewart J. Tepper
HEADACHE (2013)
Intranasal Zolmitriptan for the Treatment of Acute Migraine
Stewart J. Tepper et al.
HEADACHE (2013)
Improved Pharmacokinetics of Sumatriptan With Breath Powered Nasal Delivery of Sumatriptan Powder
Mohammad Obaidi et al.
HEADACHE (2013)
Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development
Marcelo E. Bigal et al.
HEADACHE (2013)
Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects
G. Tong et al.
JOURNAL OF HEADACHE AND PAIN (2013)
Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain
Rodrigo Noseda et al.
PAIN (2013)
Intranasal Ketorolac For Short-Term Pain Management
Karly P. Garnock-Jones
CLINICAL DRUG INVESTIGATION (2012)
The cost of headache disorders in Europe: the Eurolight project
M. Linde et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Farkkila et al.
LANCET NEUROLOGY (2012)
mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system
Dipak V. Amrutkar et al.
PAIN (2012)
Preparation and Characterization of Spray-Dried Mucoadhesive Microspheres of Ketorolac for Nasal Administration
C. D. Nagda et al.
Current Drug Delivery (2012)
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
Hans-Christoph Diener et al.
CEPHALALGIA (2011)
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
David J. Hewitt et al.
CEPHALALGIA (2011)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study
P. G. Djupesland et al.
CEPHALALGIA (2010)
Acute treatment of migraine with the selective 5-HTIF receptor agonist lasmiditan - A randomised proof-of-concept trial
Michel D. Ferrari et al.
CEPHALALGIA (2010)
Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?
Juana C. A. Marin et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Stephen F. Traynelis et al.
PHARMACOLOGICAL REVIEWS (2010)
Randomized, controlled trial of telcagepant for the acute treatment of migraine
K. M. Connor et al.
NEUROLOGY (2009)
The 'Act when Mild' (AwM) Study: a step forward in our understanding of early treatment in acute migraine
P. J. Goadsby
CEPHALALGIA (2008)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Release of glutamate and CGRP from trigeminal ganglion neurons:: Role of calcium channels and 5-HT1 receptor signaling
Yan Xiao et al.
MOLECULAR PAIN (2008)
Efficacy of zolmitriptan nasal spray in adolescent migraine
Donald W. Lewis et al.
PEDIATRICS (2007)
Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden
Marcelo Bigal et al.
HEADACHE (2007)
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo
Brianne Weiss et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Gastric stasis in migraine: More than just a paroxysmal abnormality during a migraine attack
SK Aurora et al.
HEADACHE (2006)
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists.: 1.: Potent and selective small molecule CGRP antagonists.: 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine:: The first CGRP antagonist for clinical trials in acute migraine
K Rudolf et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine
CN Sang et al.
CEPHALALGIA (2004)
Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery
S Jähnichen et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
The assessment of topical nasal drug distribution
R Aggarwal et al.
CLINICAL OTOLARYNGOLOGY (2004)
In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation
V Puri et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2004)
5-HT1F receptor agonists in acute migraine treatment:: a hypothesis
NM Ramadan et al.
CEPHALALGIA (2003)
Evidence for serotonin (5-HT)(1B), 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input
PJ Goadsby et al.
NEUROSCIENCE (2003)
Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot (R)) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison
HC Diener et al.
EUROPEAN NEUROLOGY (2002)
Advances in pharmacological treatment of migraine
HC Diener et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries:: similarity with human coronary artery
I Bouchelet et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist
H Doods et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
